MARKET

APLS

APLS

Apellis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

46.48
-1.71
-3.55%
Pre Market: 46.48 0 0.00% 08:00 05/07 EDT
OPEN
48.08
PREV CLOSE
48.19
HIGH
48.58
LOW
45.49
VOLUME
2
TURNOVER
--
52 WEEK HIGH
58.47
52 WEEK LOW
25.49
MARKET CAP
3.74B
P/E (TTM)
-9.9929
1D
5D
1M
3M
1Y
5Y
Canada Invests in Next-Generation EV Charging Networks in B.C.
Canada Invests in Next-Generation EV Charging Networks in B.C.
CNW Group · 1d ago
Terahertz Components and Systems Market Size Analysis 2021 with CAGR of 14.7%, Revenue Expectations, Trends Analysis, Global Share, Top Players and Business Prospects, Growth Opportunities and Forecast Research by 2026
May 04, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." The “Terahertz Components and Systems...
The Express Wire · 3d ago
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Analysts Are Reducing Their Forecasts For This Year
The latest analyst coverage could presage a bad day for Apellis Pharmaceuticals, Inc. ( NASDAQ:APLS ), with the...
Simply Wall St. · 3d ago
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Sio Gene Therapies (SIOX)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Apellis Pharmaceuticals (APLS) and Sio Gene Therapies
SmarterAnalyst · 4d ago
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
Following a mixed month in April, the Food and Drug Administration sets out to review another slate of drugs in May.
Benzinga · 5d ago
Is Apellis Pharmaceuticals (NASDAQ:APLS) Weighed On By Its Debt Load?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Simply Wall St. · 6d ago
Credit Suisse Keeps a Hold Rating on Apellis Pharmaceuticals (APLS)
In a report released today, Tiago Fauth from Credit Suisse maintained a Hold rating on Apellis Pharmaceuticals (APLS), with a price target of $39.00. The
SmarterAnalyst · 04/29 16:26
DJ Apellis Pharmaceuticals Is Maintained at Neutral by Credit Suisse
Dow Jones · 04/29 15:52
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of APLS. Analyze the recent business situations of Apellis through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 16 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average APLS stock price target is 70.40 with a high estimate of 130.00 and a low estimate of 39.00.
EPS
Institutional Holdings
Institutions: 219
Institutional Holdings: 73.22M
% Owned: 90.96%
Shares Outstanding: 80.50M
TypeInstitutionsShares
Increased
50
3.28M
New
36
3.06M
Decreased
60
4.84M
Sold Out
13
260.51K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.01%
Pharmaceuticals & Medical Research
-0.29%
Key Executives
Chairman/Independent Director
Gerald Chan
President/Chief Executive Officer/Co-Founder/Director
Cedric Francois
Co-Founder/Chief Operating Officer
Pascal Deschatelets
Chief Financial Officer/Treasurer
Timothy Sullivan
Senior Vice President
Victoria Brown
Senior Vice President
Thomas Lackner
Vice President - Finance/Primary Contact
Nicole Perry
Vice President/General Counsel
David Watson
Other
Federico Grossi
Director
Stephanie OBrien
Other
Lukas Scheibler
Other
Adam Townsend
Independent Director
A. Sinclair Dunlop
Independent Director
Sinclair Dunlop
Independent Director
Paul Fonteyne
Independent Director
Alec Machiels
Independent Director
Stephanie O'Brien
No Data
About APLS
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company’s lead product candidate is APL-2. APL-2 is Phase III clinical trials developed for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. It is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. The Company is developing APL-9 for intravenous administration in systemic indications.

Webull offers kinds of Apellis Pharmaceuticals Inc stock information, including NASDAQ:APLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APLS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading APLS stock methods without spending real money on the virtual paper trading platform.